一種A型和B型流感病毒檢測列表中包含了禽流感病毒H5N1分離株。該檢測方法已經獲得了美國食品藥品管理局的許可。

這種檢測方法是由Binax公司研制開發的，該公司是Inverness醫學創新公司(Waltham, MA, USA)的分支機構，該檢測方法叫做BinaxNOW流感A和B檢測。這種檢測是一種一步法快速檢測，能夠在15分鐘之內準確區別出流感病毒A和B型。即配即用型檢測能夠在流感爆發的時候有效地對患者作出診斷。

經過確證的診斷方法能夠幫助醫務工作者選擇合適的治療方法，在疾病早期的時候采取干預措施。抗病毒治療能夠減少癥狀的嚴重程度，縮短疾病的病程，降低患者傳染給其它人的時間。因為開始病毒治療的時間窗只在出現癥狀的48小時之內，能夠早期診斷的重要性是不言而喻的。

Inverness醫療創新公司是一家在全球范圍內處于領先地位的體外診斷產品供應商，該公司現在正在為其水平流體免疫檢測和其它用于各種診斷方法的技術開拓機會。

Influenza Panel Includes H5N1
 
A test for influenza A and B now includes avian influenza H5N1 isolates in its list of influenza strains. The test has been cleared by the U.S. Food and Drug Administration (FDA).

The test was developed by Binax Inc., a subsidiary of Inverness Medical Innovations (Waltham, MA, USA), and is called the BinaxNOW influenza A and B test. The test is a one-step, rapid test that is able to clearly differentiate between influenza A and influenza B in 15 minutes. Use of the easy-to-read test can help diagnose patients efficiently in the event of an outbreak of influenza.

A confirmed diagnosis helps healthcare workers to select appropriate treatments and to begin administration early in the process. Antivirals can reduce the severity of symptoms, shorten the duration of illness, and reduce the time during which patients can be infectious to others. Since the window of opportunity to begin antiviral treatment is only 48 hours from the onset of symptoms, these capabilities are very important.

Inverness Medical Innovations is a leading global provider of in vitro diagnostic products that is now exploring new opportunities for its lateral flow immunoassay and other proprietary technologies for various professional diagnostic applications.